You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 14, 2025

Patent: 10,093,689


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,093,689
Title:Composition containing a gold (I) complex and cancer cells
Abstract: Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.
Inventor(s): Al-Jaroudi; Said S. (Dhahran, SA), Alhoshani; Ali (Riyadh, SA), Altaf; Muhammad (Dhahran, SA), Isab; Anvarhusein Abdulkadir (Dhahran, SA)
Assignee: King Fahd University of Petroleum and Minerals (Dhahran, SA) King Saud University (Riyadh, SA)
Application Number:15/990,289
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,093,689

Introduction

Patents are a crucial component of intellectual property law, providing inventors with exclusive rights to their inventions in exchange for public disclosure. This analysis will delve into the specifics of United States Patent 10,093,689, examining its claims, the broader patent landscape, and the implications of such patents.

Understanding Patents and Their Purpose

Patents serve as a legal mechanism to protect inventions, allowing inventors to exclude others from making, using, offering for sale, or selling their invention for a limited time. In return, the inventor must publicly disclose the technical details of the invention[1].

The Patent in Question: 10,093,689

To analyze the claims of United States Patent 10,093,689, one must first identify the invention and its technical details. However, without specific details from the patent itself, we can discuss the general process and importance of patent claims.

Claims Analysis

Patent claims are the heart of any patent, defining the scope of protection granted to the inventor. These claims must be novel, nonobvious, and directed to patent-eligible subject matter. The novelty requirement ensures that the claimed invention is new and not previously disclosed in the prior art. The nonobviousness requirement ensures that the invention is significantly different from existing knowledge and not obvious to a person of ordinary skill in the field[2].

The Broader Patent Landscape

Global and Cross-National Activity

The United States Patent and Trademark Office (USPTO) grants patents to inventors worldwide. In 2016, the USPTO granted over 300,000 patents, with nearly half going to U.S. inventors, followed by Japan and the European Union. This global activity highlights the international nature of patenting and innovation[1].

Industry-Level Patenting

High-technology manufacturing and commercial knowledge-intensive services industries dominate the patent landscape. In the U.S., these industries received a significant majority of patents granted in 2015, with high-technology manufacturing industries accounting for 61% of patents in the manufacturing sector and commercial knowledge-intensive services receiving 87% of patents in non-manufacturing industries[1].

Patent Trial and Appeal Board (PTAB) and Inter Partes Review

The Leahy-Smith America Invents Act (AIA) of 2011 introduced significant changes to U.S. patent law, including the creation of the PTAB. This board allows for administrative challenges to the validity of patents, such as Inter Partes Review (IPR) and Post-Grant Review (PGR). These processes are often faster and less expensive than judicial proceedings, making them a preferred method for challenging patent validity[2].

Advanced Patent Searching Techniques

To fully understand the patent landscape surrounding a specific patent like 10,093,689, advanced patent searching techniques are essential. These involve analyzing patent families, which include related patents filed in different jurisdictions. This process is complex due to variations in claims, multi-jurisdiction filing, and language barriers[3].

National Security and Patent Secrecy

The Invention Secrecy Act of 1951 mandates the review of patent applications that could be detrimental to national security. The USPTO, in collaboration with defense agencies, screens submissions and may impose Secrecy Orders to prevent the disclosure of sensitive inventions. This process highlights the critical balance between intellectual property protection and national security[5].

Key Players in the Patent Landscape

Major organizations like IBM, Samsung, Canon, Qualcomm, and Google are among the top recipients of USPTO patents. These companies drive innovation and patent activity, often focusing on high-technology and knowledge-intensive sectors[1].

Challenges and Criticisms

The PTAB and IPR processes, while intended to improve patent quality, have faced criticism. Some argue that these processes make it too easy to challenge patents, creating uncertainty and potentially stifling innovation. This debate underscores the ongoing need for a balanced approach to patent law and enforcement[2].

International Collaborations

Initiatives like the US-JP Collaborative Search Pilot Program between the USPTO and the Japan Patent Office (JPO) facilitate international cooperation in patent examination. Such programs can streamline the patenting process and enhance the quality of patents granted globally[4].

Conclusion

Analyzing the claims and patent landscape of a specific patent like 10,093,689 involves a deep dive into the technical details of the invention, the broader industry trends, and the legal frameworks governing patents. Here are some key takeaways:

  • Patent Claims: Must be novel, nonobvious, and directed to patent-eligible subject matter.
  • Global Patent Trends: The USPTO grants patents to inventors worldwide, with significant activity from the U.S., Japan, and the EU.
  • Industry Dominance: High-technology manufacturing and commercial knowledge-intensive services dominate patent activity.
  • PTAB and IPR: Administrative challenges to patent validity are faster and less expensive than judicial proceedings but face criticism for potentially stifling innovation.
  • National Security: Patent secrecy orders are used to protect inventions that could be detrimental to national security.
  • International Collaborations: Programs like the US-JP Collaborative Search Pilot Program enhance international cooperation in patent examination.

Key Takeaways

  • Understanding Patent Claims: Critical for defining the scope of protection.
  • Global Patent Activity: Reflects international innovation trends.
  • Industry Focus: High-technology and knowledge-intensive sectors are key drivers.
  • Administrative Challenges: PTAB and IPR processes impact patent validity and innovation.
  • National Security Considerations: Balance between intellectual property protection and national security.
  • International Cooperation: Enhances the efficiency and quality of patent examination.

FAQs

Q: What is the primary purpose of patenting? A: The primary purpose of patenting is to allow inventors to gain economic benefits from their inventions in exchange for public disclosure of the technical information.

Q: Which industries dominate patent activity in the U.S.? A: High-technology manufacturing and commercial knowledge-intensive services industries dominate patent activity in the U.S.

Q: What is the role of the Patent Trial and Appeal Board (PTAB)? A: The PTAB is a tribunal within the USPTO that hears administrative challenges to the validity of patents, such as Inter Partes Review (IPR) and Post-Grant Review (PGR).

Q: How do national security considerations affect patent applications? A: The Invention Secrecy Act of 1951 allows for the imposition of Secrecy Orders on patent applications that could be detrimental to national security, preventing their disclosure and publication.

Q: What is the significance of international collaborations in patent examination? A: International collaborations, such as the US-JP Collaborative Search Pilot Program, streamline the patent examination process and enhance the quality of patents granted globally.

Sources

  1. National Science Foundation. "Invention, Knowledge Transfer, and Innovation." Chapter 8, NSB 20181 Report.
  2. Congressional Research Service. "The Patent Trial and Appeal Board and Inter Partes Review."
  3. CAS.org. "Advanced patent searching techniques - CAS.org."
  4. Japan Patent Office. "US-JP Collaborative Search Pilot Program."
  5. Defense Technology Security Administration. "Patent Security Reviews."

More… ↓

⤷  Try for Free

Details for Patent 10,093,689

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 January 10, 1978 10,093,689 2036-04-22
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 10,093,689 2036-04-22
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 September 25, 1998 10,093,689 2036-04-22
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 February 10, 2017 10,093,689 2036-04-22
Eli Lilly And Company ERBITUX cetuximab Injection 125084 February 12, 2004 10,093,689 2036-04-22
Eli Lilly And Company ERBITUX cetuximab Injection 125084 March 28, 2007 10,093,689 2036-04-22
Genentech, Inc. AVASTIN bevacizumab Injection 125085 February 26, 2004 10,093,689 2036-04-22
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 7 of 7 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.